The pharmaceutical company failed to inform the FDA of manipulated data when the gene therapy was under review and could face a legal battle.
List view / Grid view
Spinal Muscular Atrophy
Filter the results
A number of drugs currently in their late stages in the development process could see competition for nusinersen, the only current SMA treatment, rise...